TY  - JOUR
AU  - Garrido, P
AU  - Hladun, R
AU  - de Álava, E
AU  - Álvarez, R
AU  - Bautista, F
AU  - López-Ríos, F
AU  - Colomer, R
AU  - Rojo, F
PY  - 2021
DO  - 10.1007/s12094-021-02558-0
UR  - http://hdl.handle.net/10668/17220
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionised the diagnostic and clinical...
LA  - en
KW  - Gene fusions
KW  - Molecular oncology
KW  - Mutations
KW  - Neoplasm
KW  - Target therapies
KW  - Adult
KW  - Age Factors
KW  - Benzamides
KW  - Child
KW  - Consensus
KW  - High-Throughput Nucleotide Sequencing
KW  - Humans
KW  - Immunohistochemistry
KW  - In Situ Hybridization, Fluorescence
KW  - Indazoles
KW  - Membrane Glycoproteins
KW  - Molecular Targeted Therapy
KW  - Neoplasms
KW  - Oncogene Proteins, Fusion
KW  - Protein Kinase Inhibitors
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Receptor, trkA
KW  - Receptor, trkB
KW  - Receptor, trkC
KW  - Reverse Transcriptase Polymerase Chain Reaction
KW  - Societies, Medical
KW  - Spain
TI  - Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
TY  - research article
VL  - 23
ER  -